Skip to main content

InMed Pharmaceuticals, Inc. (INM)

NASDAQ: INM · Delayed Price · USD
1.81 -0.02 (-1.09%)
Sep 24, 2021 10:47 AM EDT - Market closed
Market Cap16.81M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out8.94M
EPS (ttm)-1.51
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume175,230
Open1.86
Previous Close1.83
Day's Range1.76 - 1.91
52-Week Range1.76 - 6.42
Beta1.41
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About INM

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including d...

IndustryBiotechnology
CEOEric Adams
CountryCanada
Stock ExchangeNASDAQ
Ticker SymbolINM
Full Company Profile

Financial Performance

Financial Statements

News

Cannabinoids Company InMed Pharma Posts Smaller Net Loss For FY21

InMed Pharmaceuticals Inc (NASDAQ: INM) reported an FY21 EPS loss of $(1.52) narrower than $(1.71) posted a year ago. On June 30, the company's cash, cash equivalents, and short-term investments were $7...

6 hours ago - Benzinga

InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update

VANCOUVER, British Columbia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannab...

8 hours ago - GlobeNewsWire

InMed Pharmaceuticals (INM): Acquiring BayMedica

LONDON, UK / ACCESSWIRE / September 20, 2021 / InMed has announced that it has entered into a definitive agreement to acquire BayMedica, a private US-based company that is focusing on the manufacture an...

4 days ago - Accesswire

InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021

VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannab...

1 week ago - GlobeNewsWire

InMed Pharmaceuticals To Acquire BayMedica, Rare Cannabinoid Manufacturer, For ~$3.66M

InMed Pharmaceuticals (NASDAQ: INM) announced on Monday that it has entered into a definitive agreement to acquire BayMedica Inc., a private company that manufactures rare cannabinoids. Once the agreeme...

1 week ago - Benzinga

InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cann...

Establishes leadership position in manufacturing and commercialization of rare cannabinoids Positions InMed within large and growing consumer health and wellness cannabinoid markets

1 week ago - Benzinga

InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannab...

2 weeks ago - GlobeNewsWire

InMed Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com September 8th

VANCOUVER, BC, Sept. 7, 2021 /PRNewswire/ -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the manufacturing and development of rare cannabinoids, announced that Eric.

2 weeks ago - PRNewsWire

InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production Of Rare Cannabinoids At Pharmaceutical Levels

Canadian clinical-stage drug development company InMed Pharmaceuticals is working to achieve pharmaceutical approval of rare cannabinoids

4 weeks ago - Benzinga

InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference

VANCOUVER, British Columbia, Aug. 12, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical d...

1 month ago - GlobeNewsWire

InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Priced At-the-Market under Nasdaq Rules

VANCOUVER, British Columbia, July 02, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical d...

2 months ago - GlobeNewsWire

InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cann...

VANCOUVER, British Columbia, June 29, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical d...

2 months ago - GlobeNewsWire

InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production

VANCOUVER, British Columbia, June 17, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical d...

3 months ago - GlobeNewsWire

InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference

VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical d...

3 months ago - GlobeNewsWire

InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results

VANCOUVER, British Columbia, May 13, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM), a clinical-stage company developing pharmaceutical-based drug candidates...

4 months ago - GlobeNewsWire

InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results

VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM; TSX:IN), a clinical-stage company developing pharmaceutical-based drug ca...

4 months ago - GlobeNewsWire

InMed to Present at Canaccord Genuity's 5th Annual Global Cannabis Conference on May 11th, 2021

VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceu...

4 months ago - GlobeNewsWire

InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial f...

VANCOUVER, British Columbia, April 28, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a world leader in the clinical development of cannabinol (“CB...

4 months ago - GlobeNewsWire

InMed Pharmaceuticals Announces Voluntary Delisting from TSX

All common shares will continue to be listed and tradable on the Nasdaq All common shares will continue to be listed and tradable on the Nasdaq

4 months ago - GlobeNewsWire

InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™

This yield level demonstrates commercial viability; supports advancing to large-scale production This yield level demonstrates commercial viability; supports advancing to large-scale production

4 months ago - GlobeNewsWire

InMed to Present at Virtual Conferences in March 2021

VANCOUVER, British Columbia, March 03, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmac...

6 months ago - GlobeNewsWire

InMed Announces Closing of US$4.5 Million Private Placement

VANCOUVER, BC, Feb. 16, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseas...

7 months ago - PRNewsWire

InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results

VANCOUVER, BC, Feb. 11, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseas...

7 months ago - PRNewsWire

InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results

VANCOUVER, BC, Feb. 5, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting disease...

7 months ago - PRNewsWire